Cyclic nucleotide phosphodiesterases (PDEs) comprise a superfamily of enzymes that serve as drug targets in many human diseases. There is a continuing need to identify high-specificity inhibitors that affect individual PDE families or even subtypes within a single family. The authors describe a fission yeast-based high-throughput screen to detect inhibitors of heterologously expressed adenosine 3′,5′-cyclic monophosphate (cAMP) PDEs. The utility of this system is demonstrated by the construction and characterization of strains that express mammalian PDE2A, PDE4A, PDE4B, and PDE8A and respond appropriately to known PDE2A and PDE4 inhibitors. High-throughput screens of 2 bioactive compound libraries for PDE inhibitors using strains expressing PDE2A, PDE4A, PDE4B, and the yeast PDE Cgs2 identified known PDE inhibitors and members of compound classes associated with PDE inhibition. The authors verified that the furanocoumarin imperatorin is a PDE4 inhibitor based on its ability to produce a PDE4-specific elevation of cAMP levels. This platform can be used to identify PDE activators, as well as genes encoding PDE regulators, which could serve as targets for future drug screens. (Journal of Biomolecular Screening 2008:62-71) 
INTRODUCTION
H IGH-THROUGHPUT SCREENS (HTS) allow one to test a large number of compounds for a desired property, leading to the identification of compounds for use as research tools or therapeutics. Such screens may be conducted in vitro using protein extracts or purified reagents. Alternatively, one can use cells whose growth or other behavior is altered by compounds of interest. The yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe are popular model eukaryotes due to the ease of genetic manipulation, through both classical and molecular genetic approaches. These yeasts carry out many biological processes in common with human cells, while allowing researchers to use simple growth phenotypes to follow the status of the process in question. These same features commend the use of these yeasts in HTS to detect compounds that alter the activity of heterologously expressed proteins that replace an endogenous protein in the host strain.
Adenosine 3′,5′-cyclic monophosphate (cAMP) signaling pathways in mammals respond to the detection of hormones, odorants, and neurotransmitters and are complicated because of the presence of multiple cAMP-producing adenylyl cyclases and cAMP-destroying cAMP phosphodiesterases (PDEs). 1, 2 There are 11 mammalian PDE families encoded by 21 genes, which produce more than 100 isoenzymes. 2, 3 PDEs from the PDE4, PDE7, and PDE8 families specifically act on cAMP; PDEs from the PDE1, PDE2, PDE3, PDE10, and PDE11 families act on both cAMP and cyclic guanosine monophosphate (cGMP); and PDEs from the PDE5, PDE6, and PDE9 families act specifically on cGMP. The presence of multiple PDE isoenzymes in various tissues complicates efforts to determine the relative roles of specific enzymes in any given biological process. Even so, chemical inhibitors of PDEs, and in some cases chemical activators, are seen as potential therapeutic compounds for the treatment of a variety of conditions including neurological diseases such as anxiety, depression, and Alzheimer's disease; inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and pulmonary hypertension; metabolic diseases such as diabetes and obesity; and other conditions such as memory loss, chronic lymphocytic leukemia, prostate cancer, and erectile dysfunction. [2] [3] [4] [5] [6] [7] [8] [9] We describe here the development of a cell-based screen for identifying both chemical inhibitors and activators of cAMP PDEs using a simple growth assay in the fission yeast S. pombe. This screening platform makes use of 2 reporters expressed from the glucose-repressible fbp1 + promoter. 10 S. pombe detects glucose via a cAMP signaling pathway to activate the cAMP-dependent protein kinase PKA, which represses fbp1 + transcription. 11, 12 Proteins required for cAMP signaling include the Git3 G protein-coupled receptor (GPCR) and its cognate heterotrimeric G protein composed of the Gpa2 Gα subunit, the Git5 Gβ subunit, and the Git11 Gγ subunit. Meanwhile, glucose starvation activates the Spc1/Sty1 stress-activated mitogen activated protein kinase pathway required for fbp1 + transcription. [13] [14] [15] The fbp1-ura4 reporter places uracil biosynthesis under the control of the glucose/cAMP pathway, such that cells with high cAMP levels due to glucose signaling repress reporter expression and cannot grow in medium lacking uracil (SC-ura) but do grow in medium containing the pyrimidine analog 5-fluoro-orotic acid (5FOA; Fig. 1A ). In contrast, cells with low cAMP levels due to defects in glucose signaling express the reporter. This allows growth in medium lacking uracil but not in 5FOA medium (Fig. 1B) . A 2nd reporter, fbp1-lacZ, allows for easy quantitation of expression from the fbp1 + promoter.
We show here that strains expressing the mammalian enzymes PDE2A, PDE4A, PDE4B, and PDE8A produce functional PDEs whose activities affect the expression of these fbp1-driven reporters. In addition, reporter expression in PDE4A-and PDE4B-expressing strains is repressed by the PDE4 inhibitor rolipram, whereas reporter expression in a PDE2A-expressing strain is repressed by the PDE2A inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA). Results from HTS for chemical inhibitors of the PDE2A, PDE4A, PDE4B, and yeast PDE Cgs2 validate the utility of this platform by identifying known PDE inhibitors and novel candidate inhibitors. One such candidate, imperatorin, was verified to inhibit PDE4 enzymes by its ability to produce a PDE4-specific elevation in cAMP levels. We discuss the additional capabilities of this screening platform to identify chemical activators of PDEs, as well as genes that encode biological activators or inhibitors of PDEs, which could serve as target proteins in future drug screens. The flexibility and versatility of this system suggest that this should be an effective way to identify both chemical and biological regulators of PDEs from a variety of organisms.
MATERIALS AND METHODS

Strains, media, and general techniques
Strains used are listed in Table 1 . Methods for yeast growth and transformations have been previously described. 16 Murine PDE genes were amplified by PCR using oligonucleotides containing approximately 60 nt of sequence flanking the S. pombe cgs2 + gene to direct homologous recombination to this locus.
FIG. 1.
Schematic of adenosine 3′,5′-cyclic monophosphate (cAMP)-regulated growth phenotypes in fission yeast strains expressing the fbp1-ura4 reporter. (A) Glucose signaling leads to adenylyl cyclase activation and a cAMP signal, which activates protein kinase A (PKA) to repress fbp1-ura4 transcription. These cells cannot grow in medium lacking uracil (-Ura) but do grow in medium containing 5-fluoro-orotic acid (5FOA). (B) Cells carrying mutations in genes required for glucose signaling have reduced adenylyl cyclase activity to lower cAMP levels. This results in low PKA activity and a failure to repress fbp1-ura4 transcription. These cells grow in medium lacking uracil (-Ura) but do not grow in medium containing 5FOA. (C) A screen for cyclic nucleotide phosphodiesterase (PDE) activators can be carried out by taking a strain such as the one in panel A and screening for compounds that enhance growth in medium lacking uracil. The compounds identified will include ones that stimulate PDE activity to lower cAMP levels. (D) A screen for PDE inhibitors can be carried out by taking a strain such as the one in panel B and screening for compounds that enhance growth in 5FOA medium. The compounds identified will include ones that inhibit PDE activity to raise cAMP levels.
The recipient strain carries a ura4 + -marked disruption of cgs2 + (also referred to as pde1 + ) 17 to allow for 5FOA counterselection for candidate transformants. PCR was used to confirm the homologous integration events. Subsequent strains were constructed by standard genetic crosses and tetrad dissection to introduce the fbp1-lacZ and fbp1-ura4 reporters as well as the pap1Δ allele.
β-Galactosidase assays and characterization of 5FOA sensitivity were carried out as previously described. 10 cAMP assays were performed on exponential phase cells grown in EMM complete medium (3% glucose) using the Assay Designs cAMP EIA kit, according to the manufacturer's instructions.
HTS
HTS were carried out at the Broad Institute's Chemical Biology Program screening facility. Depending on the strain, cultures were pregrown to exponential phase in EMM complete medium containing from 0.5 to 2.5 mM cAMP to repress fbp1-ura4 transcription. Cells were collected by centrifugation and resuspended in 5FOA medium, and 25 μl was transferred to 384-well microtiter dishes (untreated, with flat clear bottoms) that had been prefilled with 25 μl 5FOA medium and prepinned with 100 nl of compounds (stock solutions were generally 10 mM) from a subset of the Prestwick Bioactive and the Microsource Spectrum compound libraries. Starting cell concentrations ranged from 0.5 × 10 5 to 4 × 10 5 cells/ml depending on the screening strain. As appropriate, control plates received either 100 nl 10 mM rolipram or DMSO. Other positive control dishes contained 5 mM cAMP in the 5FOA medium. Cultures were grown for 48 h at 30 °C while sealed in an airtight container with moist paper towels to prevent evaporation. Optical densities (OD 600 ) of cultures were measured using a microplate reader. Bioinformatic analysis of the results to determine composite Z scores was performed as previously described. 18, 19 The Z factor of an assay is determined by multiplying the sum of the standard deviations of the positive and negative controls by 3 and dividing by the absolute difference in the means of the positive and negative controls. This value is then subtracted from the number 1 to obtain the Z factor. An assay with a Z factor of greater than 0.5 is considered to be sufficiently robust for HTS. Within a screen, individual wells are assigned a Z score, which represents the number of standard deviations above or below the mean of the negative controls within that same assay plate. Duplicate Z scores for each compound are plotted onto a grid and projected perpendicularly to the diagonal that represents identity between duplicate Z scores. The composite Z score is the distance from this point on the diagonal to the origin.
RESULTS
Construction of fission yeast strains expressing mammalian PDEs
In an effort to develop yeast strains whose growth behaviors could serve as a reflection of the activity of heterologously expressed PDEs, we used homologous recombination to replace the only S. pombe PDE gene, cgs2 + , with each of 4 murine PDE genes, PDE2A, PDE4A, PDE4B, and PDE8A. [20] [21] [22] Strains expressing these enzymes regain mating competence, which is deficient in strains lacking PDE activity, 23 indicating that these PDEs are functional when expressed in S. pombe (data not shown).
We next constructed strains expressing the murine PDEs together with the fbp1-driven reporters and carrying mutant alleles of either the git3 + glucose receptor gene or the gpa2 + Gα subunit gene, both of which are required for glucose detection, adenylyl cyclase activation, and transcriptional repression of the fbp1-ura4 and fbp1-lacZ reporters. 11, [24] [25] [26] The relative level of reporter expression reflects PDE activity. β-Galactosidase activity in the gpa2mutant strains, as compared with similar strains expressing either the wild-type S. pombe Cgs2 + PDE or the frame-shifted, and presumably inactive, Cgs2-2 truncated PDE, 16 demonstrate that all 4 murine PDEs are active in S. pombe ( Table 2 ; vehicle values). The relative level of PDE activity, as reflected by the degree to which β-galactosidase activity is elevated by the reduction in cAMP levels, is Cgs2 + > PDE4A > PDE2A ≥ PDE4B ≥ PDE8A > Cgs2-2. This order of activity is consistent with the ability of git3and gpa2mutations to confer 5FOA-sensitive (5FOA S ) growth to strains expressing the murine PDEs (see below).
Effect of known PDE inhibitors on reporter expression and cAMP levels
We next tested the effect of known PDE inhibitors on the expression of the fbp1-lacZ fusion in murine PDE-expressing strains. As seen in Table 2 , the PDE4 inhibitor rolipram reduces β-galactosidase activity in PDE4A-and PDE4B-expressing cells but not in Cgs2-or PDE8A-expressing cells. These results support previous studies indicating that PDE8A is insensitive to rolipram. In addition, the PDE2A inhibitor EHNA reduces βgalactosidase activity expressed from a PDE2A strain ( Table 2) with an ED 50 of approximately 14 μM. The effect on fbp1-lacZ expression is not a direct measurement of PDE activity; therefore, an IC 50 cannot be determined by these data. The ED 50 values of rolipram on PDE4A and PDE4B appear to be approximately 37 μM and 26 μM, respectively; however, these values assume that the 50-μM assays are in the linear range, which is not the case. A more accurate assessment of rolipram inhibition of PDE4A is presented below. No PDE8A inhibition was observed using dipyridamole (data not shown), a known PDE8A inhibitor. 21 As a DNA sequence analysis of the integrated PDE8A gene showed that it encodes the wild-type PDE8A protein, we presume that the failure to observe a response to dipyridamole is due to a permeability problem in fission yeast or a solubility problem with dipyridamole in the growth medium.
In an effort to increase the sensitivity to PDE inhibitors, we examined whether deleting pap1 + , encoding a zinc finger transcriptional activator required for ABC transporter expression and whose overexpression confers staurosporine-resistance, 27, 28 would enhance the inhibition of PDE4A by rolipram. As shown in Figure 2 , PDE4A-expressing cells lacking pap1 + (pap1Δ) are more sensitive (ED 50 ≈ 3.6 μM) to rolipram than pap1 + cells (ED 50 ≈ 4.2 μM). Moreover, pap1Δ strains that are 5FOA S due to low cAMP levels maintain the 5FOA S growth phenotype for longer periods of incubation than equivalent pap1 + strains (data not shown). This enhanced 5FOA sensitivity should aid in the detection of PDE inhibitors that confer 5FOA R growth.
To determine if the effect of rolipram on PDE4-expressing cells and of EHNA on PDE2A-expressing cells is through inhibition of the heterologously expressed PDEs, cAMP levels were measured before and after drug treatment. As shown in Figure  3A , cAMP levels increase within 10 min of exposure to 200 μM inhibitor and reach peak levels within 1 h. We next examined whether varying degrees of PDE inhibition could be detected by measuring cAMP levels at the 1-h time point in cells exposed to lower concentrations of inhibitor. Figure 3B shows that PDE4A is only partially inhibited by 20 μM rolipram, whereas PDE4B is completely inhibited at this concentration, suggesting that PDE4B is more sensitive than PDE4A to rolipram in this system. Furthermore, cAMP levels in a strain expressing PDE8A are completely insensitive to rolipram treatment, consistent with previous studies of PDE8A 21 and also indicating that rolipram does 
HTS of PDE-expressing strains
Although the fbp1-lacZ reporter allows for a measurement of PDE inhibition, the true power of this system is in the growth phenotype conferred by transcription of the fbp1-ura4 reporter. PDE inhibitors should restore 5FOA R growth to strains possessing low basal cAMP levels by elevating cAMP levels to repress fbp1-ura4 transcription (Fig. 1D) . Conversely, PDE activators should confer growth in SC-ura medium to strains possessing high cAMP levels by reducing cAMP levels to increase fbp1-ura4 transcription (Fig. 1C) . As mentioned earlier, mutations in either the git3 + or gpa2 + genes were introduced into various PDE-expressing strains. Although a gpa2mutant allele conferred 5FOA sensitivity on PDE2A-, PDE4A-, PDE4B-, and PDE8A-expressing strains, only Cgs2-and PDE4A-expressing strains became 5FOA S when carrying a mutant allele of git3 + (data not shown). These results are consistent with previous observations that loss of Gpa2 confers a greater defect in cAMP signaling than does loss of Git3 10, 25, 26 and that Cgs2 and PDE4A are more active than the other 3 PDEs in our strains ( Table 2) .
To determine whether the 5FOA growth phenotype could be exploited for HTS, strains expressing Cgs2, PDE2A, PDE4A, PDE4B, or PDE8A were pregrown in EMM medium containing cAMP and then transferred to 5FOA medium in 384-well microplates in the presence or absence of cAMP. OD 600 measurements were taken after 24 and 48 h of incubation at 30 °C. After 24 h, some cAMP-stimulated growth could be detected; however, 48-h incubation was required for cAMP-treated cells to grow to saturation (data not shown). Similar experiments in which 20 μM rolipram (final concentration) was pinned into 192 of the 384 wells, in place of cAMP addition to the medium, produced 5FOA R growth in the PDE4A-and PDE4B-expressing strains. In a typical experiment with CHP1113 cells (PDE4B), the OD 600 of the rolipram-treated cultures was 1.28 ± 0.07, whereas the OD 600 of the untreated wells was 0.18 ± 0.02. When using CHP1098 cells (PDE4A), the OD 600 of the rolipram-treated cultures was 1.15 ± 0.06, whereas the OD 600 of the untreated wells was 0.2 ± 0.03. The Z factors (a statistical assessment of the quality of data sets used in HTS 29 ) for these screens were 0.76 and 0.72, respectively, placing them well above the 0.5 minimum Z factor indicative of a robust screen.
As mentioned above, cAMP was present in the growth medium prior to transferring cells to the 5FOA medium. 5FOA sensitivity is due to the presence of the Ura4 protein, so that cultures had to be pregrown under conditions that repress fbp1-ura4 + reporter expression. The effect of the PDE inhibitor is therefore to maintain 5FOA resistance rather than to confer it during the assay. As shown in Figure 4 , CHP1113 cells (PDE4B3 gpa2Δ) are only able to respond to exposure to either cAMP or rolipram addition to the 5FOA medium if they are precultured in the presence of at least 0.25 mM cAMP.
To test the utility of this system, we screened a pair of libraries containing 3120 bioactive compounds, including known PDE inhibitors, using 5FOA S strains expressing PDE2A, PDE4A, PDE4B, or Cgs2 for compounds that confer 5FOA R growth. Duplicate plates were screened, and compounds that Figure 5 is a Venn diagram displaying the overlap of the compounds identified in these 4 screens. These screens identified relatively low numbers of compounds (from 0.8% to 3.2% of compounds tested per strain), which included known PDE4 inhibitors such as rolipram and zardaverine as PDE4-specific inhibitors (Fig. 6) . Also identified were compounds of classes that include known PDE inhibitors as discussed below.
To validate the identification of one of the candidate inhibitors, we reexamined the known PDE4-specific inhibitor rolipram, together with the candidate PDE4 inhibitor imperatorin ( Fig. 6) to determine an ED 50 (effective dose required to promote 5FOA-resistant growth to half of the cAMP-stimulated level) with respect to the 5FOA growth assay. We also examined the ability of imperatorin to elevate cAMP levels, indicative of PDE inhibition. As shown in Figure 7A , and similar to Figure 3B , rolipram elevates cAMP levels in both PDE4A-and PDE4B-expressing cells. Consistent with the composite Z scores for imperatorin in the HTS (Fig. 6) , imperatorin significantly increases cAMP levels in a PDE4B-expressing strain (composite Z = 50.43) but only modestly increases cAMP levels in a PDE4A-expressing strain (composite Z = 15.53). This is a PDE4-specific effect, as imperatorin has no significant effect on cAMP levels in a PDE2A-expressing strain (data not shown). Dose-response curves for imperatorin and rolipram with respect to stimulation of 5FOA-resistant growth were also carried out (Fig. 7B) . Similar to the results from the cAMP assays and the HTS, rolipram is highly effective on both PDE4A (ED 50 = 25.9 μM) and PDE4B (ED 50 = 1.5 μM), whereas imperatorin is significantly more active against PDE4B (ED 50 = 40 μM) than PDE4A (no significant growth). These data confirm that imperatorin is an effective PDE4B inhibitor and demonstrate our ability to assess PDE inhibitors by cAMP elevation and 5FOA-resistant growth, as well as by their effect on fbp1-lacZ expression (Table 2, Fig. 2 ).
DISCUSSION
We have described a novel fission yeast cell-based screening platform, amenable for HTS to identify compounds that alter PDE activity. Although a budding yeast system based on heat shock sensitivity of stationary-phase cells has been previously reported, 30 cells in that assay had to be exposed to 0.5 mM to 2 mM rolipram to detect an effect on PDE4B. 31, 32 In contrast, we have successfully screened compound libraries at an average concentration of 20 μM to detect both known and previously unidentified PDE inhibitors (Fig. 6) . We have gone on to determine ED 50 values for rolipram against PDE4A and PDE4B of 25.9 μM and 1.5 μM, respectively. These values are higher than the IC 50 values for rolipram against PDE4 enzymes (generally in the range of 1 μM) 2 ; however, cell-based assays cannot be as sensitive as in vitro assays because of additional requirements of cell permeability and the presence of thousands of proteins within a cell, some of which may bind to the compound and reduce its availability to the target protein. In fact, it is even unclear how the intracellular concentration of rolipram relates to the concentration in the growth medium. In addition, we observe a significant difference in the ED 50 for rolipram against PDE4A and PDE4B that is not consistent with in vitro measurements. This may reflect the fact that PDE4B appears to be less active than PDE4A in our strains ( Table 2) ; thus, less inhibition is required to produce an effect on reporter expression. This is consistent with the lower ED 50 of rolipram against PDE4A for repression of β-galactosidase expression (3-4 μM) than for 5FOA-resistant growth (25.9 μM) . For strains that express the reporter genes at a high level due to high initial PDE activity, a greater reduction in reporter expression is required to produce 5FOA-resistant growth.
Using this inexpensive assay, developing a large collection of strains expressing either mammalian cAMP-specific or dualspecificity PDEs will be straightforward. This platform can also be used with PDEs from pathogens, whose inhibition may either kill the target pathogen or reduce virulence. Strains representing a broad panel of PDEs could be used to identify compounds possessing desirable specificity profiles to suggest the potential of individual compounds as candidate therapeutics. Moreover, because this platform identifies compounds based on stimulation of cell growth, it will not detect compounds that, although inhibiting PDEs in vitro, are too cytotoxic or cell impermeable for therapeutic use. The compounds identified in this screen must also remain active within the yeast for much of the 48-h incubation period to promote significant cell growth. This is not the case for most PDE assays, which are carried out in vitro on purified proteins or on protein extracts over a short time course. In addition, this cell-based screening platform should be able to detect PDE inhibitors that may not be identified by in vitro screens. For example, compounds that prevent either intermolecular or intramolecular interactions required for enzyme formation would be overlooked in an in vitro assay on purified enzymes or protein extracts yet should be identifiable in this assay.
This screening platform is not meant to replace in vitro assays that are well established as a means of identifying and characterizing PDE inhibitors. Clearly, there are disadvantages of not being able to identify compounds that are not soluble in the yeast growth medium or are not permeable to the yeast cells-problems not encountered in an in vitro assay. However, our screen may represent a more holistic approach to drug discovery that identifies compounds with favorable druglike qualities beyond having a low IC 50 for the target enzyme.
Where this approach may show the greatest advantage over the in vitro assays is in identifying compounds that selectively inhibit PDEs within a single family, such as PDE4. Although there has been significant interest in PDE4 inhibitors based on the CNS and anti-inflammatory effect of rolipram and other PDE4-specific inhibitors for the past 25 years, 33, 34 no such inhibitor has received approval of the Food and Drug Administration. This is largely due to an emetic side effect that is thought to be caused by PDE4D inhibition. 35, 36 Structural approaches to PDE4 inhibition focus on the highly conserved active sites, making it unlikely to find compounds that display a significant difference in IC 50 values against the PDE4 subtypes. As this cell-based assay can theoretically detect compounds that work by mechanisms other than binding to PDE active sites, there is the potential for identifying subtypeselective compounds.
The pilot HTS against 3120 bioactive compounds using strains expressing the yeast PDE Cgs2 or the murine PDEs 2A, 4A, and 4B identified a number of compounds that promote 5FOA R growth, presumably by inhibiting the target PDEs to raise cAMP levels. These included the known PDE4 inhibitors rolipram and zardaverine, which affected only the PDE4A-and PDE4Bexpressing strains (Fig. 6) . Other compounds identified include coumarins, furanocoumarins, and furanochromones ( Fig. 6) , as well as flavonoids and steroids (not shown). Members of these compound classes are known to have PDE-inhibitory properties, 37 including the furanocourmarin trioxsalen, furanochromones khellin, and visnagin, 38, 39 although most of these compounds identified had not been shown to be PDE inhibitors. Interestingly, both rolipram and imperatorin had been previously shown to inhibit HIV replication, 40, 41 although the mechanism of imperatorin action was unknown. We demonstrate here that imperatorin is an effective PDE4B inhibitor, although its effect on PDE4A is very modest (Fig. 7) . As with imperatorin, many compounds identified in our screens display therapeutic potential, in the absence of a complete understanding of their mechanism. Therefore, data from these screens will help to partially elucidate the effect of these compounds on mammalian cells.
Although the relative overlap of the compounds identified in each screen further validates this platform, it also alerts us to some caveats. Candidates from the Cgs2 screen display the least overlap with candidates from the other 3 screens (Fig. 5) , consistent with the fact that the murine PDEs are more closely related to each other than to Cgs2. Furthermore, 18 compounds inhibit both PDE4A and PDE4B but not Cgs2 or PDE2A, consistent with the pharmacological grouping of PDE4A and PDE4B into the PDE4 family. On the other hand, there was an unexpected amount of overlap from the PDE2A and PDE4B screens. As these PDEs appear to be less active in fission yeast than Cgs2 and PDE4A ( Table 2) , some of these candidates may either weakly reduce fbp1-driven transcription by a cAMPindependent manner or raise cAMP levels by stimulating adenylyl cyclase activity. This later hypothesis is consistent with the presence of diterpenoids in this group of compounds. However, we should be able to distinguish among cAMP-independent effects, adenylyl cyclase activation, and PDE inhibition by measuring cAMP levels in experimental and control strains as in Figure 3B and Figure 7A . Specifically, compounds that act in a cAMP-independent manner will not affect cAMP levels in any strains, whereas compounds that activate adenylyl cyclase will elevate cAMP levels in control strains that lack PDE activity. Finally, the fact that a number of compounds were detected in only 1 of each of the 4 screens lends support for this platform as a tool for identifying isoenzyme-specific inhibitors, which could lead to the development of highly specific therapeutic compounds.
The ability to identify PDE inhibitors is based on the growth phenotype conferred by the cAMP-repressible fbp1-ura4 reporter. This system can also identify compounds that stimulate PDE activity to lower cAMP levels and increase fbp1-ura4 expression. PDE activators should confer Ura + growth to strains whose high basal cAMP levels repress fbp1-ura4 expression in the absence of drug exposure (Fig. 1C) . Finally, as yeast are capable of maintaining autonomously replicating plasmids, one could screen cDNA libraries for genes that encode biological inhibitors or activators of target PDEs, which could serve as novel targets for HTS. Thus, this screening platform has the potential for identifying novel PDE inhibitors and activators as well as new ways to moderate cAMP-signaling pathways in an effort to improve therapeutic approaches to treating a wide array of human diseases.
